A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With CRC as 3rd or Above Therapy
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2016
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Hutchison MediPharma
- 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2015 Results published in a Hutchison China MediTech media release.
- 04 Sep 2015 Detailed results from this trial will be presented at the 2015 European Cancer Congress meeting in late September, according to a Hutchison MediPharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History